SARS-CoV-2 IgG ELISA Kit |
|||
E4901-100 | Biovision | 100 assays | EUR 903.6 |
Human IgG antibody Laboratories manufactures the test for sars-cov-1 antibodies 2004 reagents distributed by Genprice. The Test For Sars-Cov-1 Antibodies 2004 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Test products are available in stock. Specificity: Test Category: For Group: Sars-Cov-1 Antibodies
SARS-CoV Spike Antibody |
||
ProSci | 0.02 mg | EUR 206.18 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
||
ProSci | 0.1 mg | EUR 523.7 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
||
ProSci | 0.02 mg | EUR 206.18 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
||
ProSci | 0.1 mg | EUR 523.7 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Matrix Antibody |
||
ProSci | 0.02 mg | EUR 206.18 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
||
ProSci | 0.1 mg | EUR 523.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
||
ProSci | 0.02 mg | EUR 206.18 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
Sars-Cov-1 Antibodies information
Porcine Foot and Mouth Disease Virus Type O Antibodies Rapid Test Kit (Colloidal gold) |
|||
abx092022-50tests | Abbexa | 50 tests | EUR 385.2 |
Porcine Reproductive and Respiratory Syndrome Virus Antibodies Rapid Test Kit (Colloidal gold) |
|||
abx092021-50tests | Abbexa | 50 tests | EUR 385.2 |
Custom Testing of Samples for Antibodies to Human Adenovirus (hAd5 hxn) by ELISA |
|||
950-100-CUX | Alpha Diagnostics | Custom | Ask for price |
Custom Testing of Samples for Antibodies to Anthrax Proteins (PA83/LF/EF) by ELISA |
|||
800-100-CUX | Alpha Diagnostics | Custom | Ask for price |
Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Rabies Vaccines by ELISA |
|||
600-020-CUX | Alpha Diagnostics | Custom | Ask for price |
Cattle and Goat Foot and Mouth Disease Virus Type O Antibodies Rapid Test Kit (Colloidal gold) |
|||
abx092023-50tests | Abbexa | 50 tests | EUR 427.2 |
Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Ovalbumin (Gal d2) by ELISA |
|||
670-140-CUX | Alpha Diagnostics | Custom | Ask for price |
Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Cholera Toxins (A/B) by ELISA |
|||
945-100-CUX | Alpha Diagnostics | Custom | Ask for price |
GENLISA™ SARS-CoV-2 (Covid-19) Surrogate Virus Neutralization Test (sVNT) ELISA |
|||
KBVH400 | Krishgen | 12 × 8 wells | EUR 3822 |
anti- SARS antibody |
|||
FNab07609 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against SARS |
Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Measles/Rubeola vaccines by ELISA |
|||
530-100-CUX | Alpha Diagnostics | Custom | Ask for price |
Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Chikungunya virus (CHIKV) by ELISA |
|||
530-400-CUX | Alpha Diagnostics | Custom | Ask for price |
Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Diphtheria Toxin/Toxoid by ELISA |
|||
940-090-CUX | Alpha Diagnostics | Custom | Ask for price |
Custom ELISA testing for anthrax antibodies in animal and human samples (vaccinated or normal) |
|||
900-100-CUX | Alpha Diagnostics | Custom | Ask for price |
Custom Testing of Samples for Antibodies Snake Venom (anti-venins from Horse/Sheep) by ELISA |
|||
570-100-CUX | Alpha Diagnostics | Custom | Ask for price |
Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Influenza A virus vaccines by ELISA |
|||
920-040-CUX | Alpha Diagnostics | Custom | Ask for price |
Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Tetanus vaccines (Toxin/Toxoid) by ELISA |
|||
930-090-CUX | Alpha Diagnostics | Custom | Ask for price |